Skip to Main Content

A $7 billion market valuation and the credibility of the entire field of RNA interference drug development is riding on the results of Alnylam Pharmaceuticals’ (ALNY) next big clinical trial.

No pressure, folks.


Before September comes to a close, Alnylam, led by CEO John Maraganore, will announce the outcome of a phase 3 clinical trial of patisiran, the company’s lead drug designed to treat a rare nerve disorder known as familial amyloid polyneuropathy (FAP.)

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Comments are closed.